The angiotensin-converting enzyme inhibitor enalapril is available for intravenous administration in the form of enalaprilat. Intravenous enalaprilat is indicated for the management of hypertension when oral therapy is not feasible. However, there are no reports of intravenous enalaprilat therapy exceeding one week in duration. We report the case of a critically ill, 39-year-old woman who received intravenous enalaprilat for the management of hypertension for a period of 21 days. The patient's blood pressure and heart rate were controlled adequately on a regimen of enalaprilat 1.25 mg iv piggyback q6h without any apparent adverse effects.
Get full access to this article
View all access options for this article.
References
1.
ReamsGPLalSMWhalenJJBauerJH. Enalaprilat: An intravenous substitute for oral enalapril therapy. Humoral and pharmacokinetic effects. J Clin Hypertens1986; 2: 245–53.
2.
RutledgeJAyersCDavidsonR, Effect of intravenous enalaprilat in moderate and severe systemic hypertension. Am J Cardiol1988; 62: 1062–7.
3.
EvansRRHenzelerMAWeberEM, The effect of intravenous enalaprilat (MK-422) administered in patients with mild to moderate essential hypertension. J Clin Pharmacol1987; 27: 415–8.
4.
Package insert. Vasotec IV (enalaprilat). West Point, PA: Merck Sharp and Dohme, October 1988.
5.
ClearyJDTaylorJW. Enalapril: A new angiotensin converting enzyme inhibitor. Drug Intell Clin Pharm1986; 20: 177–86.
6.
BrunnerHR. Long term clinical experience with enalapril in essential hypertension. J Hypertens1983; 1 (suppl 1): 103–7.
7.
DaviesROIrvinJDKramschDKWalkerJSMoncloaF. Enalapril: Worldwide experience. Am J Med1984; 77 (2A): 23–35.
8.
RucinskaEJSmallRIrvinJ. High-risk patients treated with enalapril maleate: Safety considerations. Int J Cardiol1989; 22: 249–59.
9.
GomezHJCirilloVJDaviesRO, Enalapril in congestive heart failure: Acute and chronic invasive hemodynamic evaluation. Int J Cardiol1986; 11: 37–48.
10.
PackerMLeeWHYushakMMedinaN. Comparison of captopril and enalapril in patients with severe chronic heart failure. N Engl J Med1986; 315: 847–53.
11.
DicarloLChatterjeeKParmleyWW, Enalapril: A new angiotensin-converting enzyme inhibitor in chronic heart failure: Acute and chronic hemodynamic evaluations. J Am Coll Cardiol1983; 2: 865–71.
12.
HodsmanGPBrownJJCummingAMM, Enalapril in the treatment of hypertension with renal artery stenosis. Br Med J1983; 287: 1413–7.
13.
HodsmanGPBrownJJCummingAMM, Enalapril in the treatment of hypertension with renal artery stenosis: Changes in blood pressure, renin, angiotensin I and II, renal function, and body composition. Am J Med1984; 77: 52–60.
14.
ClelandJGFDargieHJMcAlpineH, Severe hypotension after first dose of enalapril in heart failure. Br Med J1985; 291: 1309–12.
15.
RaichlenJSHealyBAcuffSGPearsonTA. Importance of risk factors in the angiographic progression of coronary artery disease. Am J Cardiol1986; 57: 66–70.
16.
FullerJHShipleyMJRoseGJarrettRJKenH. Coronary-heart-disease risk and impaired glucose tolerance. Lancet1980; 1: 1373–6.
